Researchers Database
KONDO SatoshiGraduate School of Medical Sciences Department of Oncology, Immunology and Surgery Lecturer Contact： s.kondo  med.nagoya-cu.ac.jp | |||
Last Updated :2024/04/24
Published Papers
- Satoshi Kondo; Daisuke Takagi; Satoshi Osaga; Katsuhiro Okuda; Ryoichi NakanishiPediatric Surgery International Springer Science and Business Media LLC 36 (3) 305 - 316 0179-0358 2020/03 [Refereed]
- 肺嚢胞を呈する小児疾患の診断・治療日本医事新報 4170/,22-32 2004
- 東海地区における乳児神経芽腫症例の検討近藤 知史小児がん 36 (4) 558 - 562 1999 [Refereed]
- 漏斗胸手術の変遷と成績小児外科 28/,1478-1484 1996
Books etc
- 小児がん診療ガイドライン2016年版近藤 知史 (Contributor中枢神経外胚細胞性腫瘍)金原出版 2016/08
- Topic in Thoracic SurgeryKONDO Satoshi (Joint workPectus Excavatum)INTECH 2012
- 今日の治療指針 2010年版近藤 知史 (ContributorWilms腫瘍)2010
- 呼吸器外科学改訂３版近藤 知史 (Contributor漏斗胸)2003
Research Grants & Projects
- Japan Society for the Promotion of Science：Grants-in-Aid for Scientific ResearchDate (from‐to) : 2011/04 -2015/03Author : HIYAMA Eiso; TAJIRI Tatsuro; HISHIKI Tomoro; WATANABE Kenichiro; OUE Takaharu; IDA Kohmei; KAMIMATSUSE Arata; OGURA Kaoru; ONITAKE Yoshiyuki; KONDO Satoshi; YANO MichihiroChildhood hepatic tumor international consortium (CHIC) by Japanese study group for pediatric liver tumor (JPLT) and European and North American groups analyzed 1605 cases in their passed clinical trials and made up the common staging, pathology classification, and risk-stratification criteria. Future global collaborative clinical trial named as PHITT (Pediatric Hepatoblastoma International Therapeutic Trial) were designed. This trial induces central review system of imaging diagnosis, surgical guideline, and molecular markers identified by next-generation sequencing and becomes a one enabled to be participated from Asian countries.
- Japan Society for the Promotion of Science：Grants-in-Aid for Scientific ResearchDate (from‐to) : 2010 -2012Author : KAMIMATSUSE Arata; HIYAMA Eiso; KAMEI Naomi; SOTOMARU Yusuke; OGURA Kaoru; TAJIRI Tatsuro; HISHIKI Tomoro; WATANABE Kenichiro; OUE Takaharu; KONDO Satoshi; IDA Komei; NAKAGAWARA AkiraThe cumulative survival rates of pediatric liver tumor, especially hepatoblastoma have been increased but the those of the high risk patients with distant metastasis and those of the intermediate riskpatients whose tumors are difficult to be radically resected remain poor. In this study, more than 100 hepatoblastoma tumors wereanalyzed in genomic aberrations and gene expression using microarray and molecular targets were selected. Selected targets were mainly classified in vascular growth factors, telomerase associated genes and Wnt signal related genes. Using these molecular markers, the hepatoblastoma patients were classified into three groups: low, intermediate, and high risk groups. The outcomes of these groups werealmost accorded to the clinical courses. Inhibitors and siRNA for these targets were used for cell testing in hepatoblastoma cultured cell lines and for animal testing using NOD-SCID mice with hepatoblastoma implant. These testing suggested that these targets are promising candidates as molecular targeting therapy in unfavorable hepatoblastoma.
- Japan Society for the Promotion of Science：Grants-in-Aid for Scientific ResearchDate (from‐to) : 2008 -2010Author : HIYAMA Eiso; TAJIRI Tatsuro; OUE Takaharu; KAMIMATSUSE Arata; HISHIKI Tomoro; IDA Koumei; YAMAOKA Hiroaki; NISHIMURA Shinichiro; KONDO Satoshi; WATANABE Kenichiro; YANO MichihiroWe conducted overseas research, mainly in Europe (SIOPEL) and North America(COG), on cases of hepatoblastoma, which account for over 80% of all pediatric liver tumors.. In Japan, the rate of incidence was higher than in these countries, but the incidence of pathologically small undifferentiated tumors was lower.. According to the outcome of the patients, we stratified the hepatoblastoma patients into three risk groups : standard, intermediate, and high risks and proposed new treatment protocols for each group. We also built a new pathological classification scheme and registration database, to pave the way for international collaboration in infrastructure development for clinical trials.
- Biochipを用いた神経芽腫での過剰発現遺伝子同定に関する研究Date (from‐to) : 2002 -2003
- 神経芽腫における癌抑制遺伝子候補ING1遺伝子の解析Date (from‐to) : 2000 -2001
- Japan Society for the Promotion of Science：Grants-in-Aid for Scientific ResearchDate (from‐to) : 1999 -2000Author : HASHIMOTO Takashi; KONDO Satoshi; MANABE Tadao; SUZUKI Tatsuya; KUNIMATSU Mitoshi; FATAKUCHI Mitsuru1. We have succeeded in complete withdrawing of the immuno-suppressive drugs from 2 more cases with living related liver transplantation in our institution. Now, we have totally 3 cases with immuno-tolerance after liver transplantation. 2. Indole amine 2,3-deoxygenase (EDO) which was reported by D.H Munn in 1999, . or novel immuno-suppressive proteins were searched using SELDI- Protein Chips. 3. Inhibitor of EDO was administered to the mice with liver transplantation that had naturally developed immuno-tolerance. However, we could not obtained anovel results 4. We confirmed DNA sequence of rat IDO and induction of IDO in the allogenic orthotopic liver transplantation livers.